Reza Khorasaninejad

CEO and Founder, LeadOptic · Person

Mentions

Episodes

Claims

Reza Khorasaninejad - CEO and Founder, LeadOptic. Tracked across 13 mentions in podcasts and expert conversations analyzed by Sonic.

What Reza Khorasaninejad has said

Reza Khorasaninejad raised the first $7 million in funding for LeadOptic through cold messaging on LinkedIn.

bullish·Reza Khorasaninejad

Reza Khorasaninejad was the co-inventor of one of the first efficient metasurfaces, which was featured on the cover of Science magazine in 2016 during his last year at Harvard.

neutral·Reza Khorasaninejad

LeadOptic has a 99% probability of receiving an NIH grant for lung cancer research based on its application score.

bullish·Reza Khorasaninejad

Reza Khorasaninejad raised the first $7 million in funding for LeadOptic through cold messaging on LinkedIn.

Expert perspectiveReza KhorasaninejadJun 24

Reza Khorasaninejad was the co-inventor of one of the first efficient metasurfaces, which was featured on the cover of Science magazine in 2016 during his last year at Harvard.

Expert perspectiveReza KhorasaninejadJun 24

LeadOptic has a 99% probability of receiving an NIH grant for lung cancer research based on its application score.

Expert perspectiveReza KhorasaninejadJun 24

Current lung cancer biopsy procedures have a 30% error rate, with one out of three patients having samples taken from the wrong location.

Expert perspectiveReza KhorasaninejadJun 24

The technology of metasurfaces, which combines advanced optical design and nanofabrication, can miniaturize imaging systems by a factor of thousands.

Expert perspectiveReza KhorasaninejadJun 24

LeadOptic has faced significant roadblocks from extensive paperwork requirements at large hospitals and medical centers.

Expert perspectiveReza KhorasaninejadJun 24

In a 40-patient pilot study, LeadOptic's device successfully differentiated between healthy tissue and lesions in all cases.

Expert perspectiveReza KhorasaninejadJun 24

LeadOptic expects to have encouraging results from its RISE AI training study by the end of the year.

Expert perspectiveReza KhorasaninejadJun 24

LeadOptic aims to increase the accuracy of lung cancer biopsies from the current rate of approximately 70% to over 90%.

Expert perspectiveReza KhorasaninejadJun 24

LeadOptic received FDA clearance for its medical imaging device at the end of December.

Expert perspectiveReza KhorasaninejadJun 24

LeadOptic is launching the RISE clinical study with Stanford Medicine to train its AI-based decision support models.

Expert perspectiveReza KhorasaninejadJun 24

LeadOptic was approached by an NIH program manager at a Device Talks event and encouraged to apply for a grant for lung cancer research.

Expert perspectiveReza KhorasaninejadJun 24

The first of LeadOptic's three pilot sites has completed its program and converted into a paying customer.

Expert perspectiveReza KhorasaninejadJun 24

Create a free account to see Reza Khorasaninejad's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail